Member Directory - Viral Hepatitis Working Group
Primary tabs
Chair: David Thomas
Objectives:
- Promote development of long-acting approaches to the treatment and/or prevention of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. With HCV infection, the ultimate goal is a ‘test and cure’ approach to elimination. With HBV infection, long-acting formulations to simplify treatment and prevention.
- Bring clinical, public health, and regulatory expertise to solve this pharmacological challenge by identifying the optimal drug targets and encouraging their development in partnership with Pharma.
- Prioritize existing compounds with the pharmacologic and chemical properties that support long-acting formulation.
Interested in joining?
Please submit your request and your CV to Ana Cervantes. Acceptance requires a written nomination from a Hepatitis Working Group member and majority approval.
![]() David Thomas is Director of Infectious Diseases and the Stanhope Bayne-Jones Professor of Medicine at the Johns Hopkins School of Medicine. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Dr. Bollinger is Founding Director of the Center for Clinical Global Health Education (CCGHE) and Professor of Infectious Diseases at the Johns Hopkins University (JHU) School of Medicine. Conflict of Interest: Receives royalties from emocha Health, miDiagnostics, consulting fees from Merck, Hologic, and grant funding from emocha Health. |
![]() Peggy is a Group Medical Director and Global Development lead for HCV products at AbbVie Inc. Conflict of Interest: Receives salary support from AbbVie. |
![]() Arnab is a founding PI at Calibr at Scripps Research and currently leads the chemistry group serving as Vice President of Medicinal Chemistry. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Dr. Cohen is President of the Hepatitis B Foundation, leading national and international efforts to eliminate hepatitis B through developing partnerships, capacity and strategies to improve hepatitis B and D screening, vaccination, and linkage to care. Conflict of Interest: Represents the Hepatitis B Foundation on community advisory boards for Gilead Sciences, Roche, Antios and GSK. |
![]() Dr. Feld attended medical school at the University of Toronto and then completed residency programs in Internal Medicine and Gastroenterology. Conflicts of Interest: Dr. Jordan Feld received Personal fees for scientific consulting from: Abbott, Abbvie, Gilead, Enanta, Roche. Dr. Feld reports receiving grants for research from Abbvie, Gilead, Janssen, Wako/Fujifilm |
![]() Simon Fletcher is an Executive Director at Gilead Sciences, where he leads a group focused on developing novel therapies for HBV and other chronic viral infections. Conflict of interest: Dr Fletcher is an employee and stockholder of Gilead Sciences, Inc. |
![]() Lobna Gaayeb manages the Long-Acting Technologies project at the Medicines Patent Pool. She has experience in coordinating international networks and scientific projects. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Leah Johnson, PhD, is a Senior Research Chemist in the Center for Engineered Systems at RTI International. Conflict of Interest: No real or apparent conflicts of interest to report. |
![]() Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare |
![]() Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases Johns Hopkins Bayview Medical Center. Conflict of Interest: Has no real or apparent conflicts of interest to report. |
![]() Dr. Norah Terrault is Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. Conflict of Interest: Dr. Terrault has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Gilead, CCO Hepatitis, Allergan Pharmaceuticals, Dova Pharmaceuticals, Intercept, EXIGO Management Consultants, LLC, Genetech & Roche. |
![]() Y. Grace Wang, MD is the VP of Clinical Development at Assembly Bioscience. Conflict of Interest: Has an ownership interest in Assembly Biosciences. |